Patient characteristics at study entry (all eligible patients, n = 169)
Characteristic . | Value . |
---|---|
Sex, female/male (%) | 28/141 (17/83) |
Age, y | 51 (27-60) |
IGHV unfavorable (%) | 87/91 (68) |
Unmutated* (%) | 84/129 (65) |
V3-21 mutated (%) | 4/129 (3) |
FISH karyotype (hierarchical model) | |
17p- ± others (%) | 4/160 (2.5) |
11q- ± others (except 17p-) (%) | 40/160 (25) |
+12 ± others (except 17p-, 11q-) (%) | 20/160 (12.5) |
13q- only (%) | 48/160 (30) |
Others (%) | 20/160 (12.5) |
Normal FISH karyotype (%) | 28/160 (17) |
Binet stage A, B, C† (%) | 26, 94, 46 (16, 56, 28) |
Time from diagnosis, mo | 13 (0-156) |
Chemotherapy naïve (%) | 152/167 (91) |
Serum thymidine kinase > 7 U/L (%) | 97/115 (84) |
β2M > 3.5 mg/L (%) | 47/115 (41) |
Lymphocyte doubling time < 12 mo (%) | 55/104 (53) |
White blood count > 50/nL (%) | 92/162 (57) |
Characteristic . | Value . |
---|---|
Sex, female/male (%) | 28/141 (17/83) |
Age, y | 51 (27-60) |
IGHV unfavorable (%) | 87/91 (68) |
Unmutated* (%) | 84/129 (65) |
V3-21 mutated (%) | 4/129 (3) |
FISH karyotype (hierarchical model) | |
17p- ± others (%) | 4/160 (2.5) |
11q- ± others (except 17p-) (%) | 40/160 (25) |
+12 ± others (except 17p-, 11q-) (%) | 20/160 (12.5) |
13q- only (%) | 48/160 (30) |
Others (%) | 20/160 (12.5) |
Normal FISH karyotype (%) | 28/160 (17) |
Binet stage A, B, C† (%) | 26, 94, 46 (16, 56, 28) |
Time from diagnosis, mo | 13 (0-156) |
Chemotherapy naïve (%) | 152/167 (91) |
Serum thymidine kinase > 7 U/L (%) | 97/115 (84) |
β2M > 3.5 mg/L (%) | 47/115 (41) |
Lymphocyte doubling time < 12 mo (%) | 55/104 (53) |
White blood count > 50/nL (%) | 92/162 (57) |